Search results for " Humans"

showing 10 items of 2466 documents

Intra-arterial idarubicin_lipiodol without embolization can provide prolonged complete response in hepatocellular carcinoma: A case report.

2020

International audience; Hepatocellular carcinoma is the fourth leading cause of cancer death. For unresectable intermediate-stage hepatocellular carcinoma, the standard treatment is transarterial chemoembolization. To date, the overall survival at three years remains low, and there is currently no consensus about the best anticancer agent and optimal treatment regimen. We report the case of a hepatocellular carcinoma patient with a vascular contraindication to embolization who achieved a complete response after four intra-arterial infusions of idarubicin emulsified with lipiodol. The patient maintained his response over a three-year period without any hepatocellular carcinoma treatment, dem…

MaleHepatocellular carcinoma[SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imagingmedicine.medical_treatmentGastroenterologyEthiodized Oil0302 clinical medicineMESH: Infusions Intra-ArterialMESH: Liver NeoplasmsPharmacology (medical)EmbolizationMESH: Carcinoma HepatocellularComplete responseMESH: Treatment OutcomeMESH: AgedStandard treatmentLiver Neoplasms[SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciences3. Good healthTreatment OutcomeOncology030220 oncology & carcinogenesisHepatocellular carcinomaLipiodol030211 gastroenterology & hepatologymedicine.drugmedicine.medical_specialtyIntra-arterial therapyCarcinoma HepatocellularAntineoplastic Agents[SDV.CAN]Life Sciences [q-bio]/Cancer03 medical and health sciencesMESH: Ethiodized OilInternal medicinemedicineHumansInfusions Intra-ArterialIdarubicinContraindicationAgedMESH: Humansbusiness.industryMESH: Idarubicinmedicine.diseasedigestive system diseasesMESH: MaleRegimenMESH: Antineoplastic AgentsbusinessIdarubicin
researchProduct

A novel mutation of gene CBFA1/RUNX2 in cleidocranial dysplasia.

2007

Cleidocranial dysplasia (CCD) is an autosomal dominant skeletal dysplasia characterised by abnormal clavicles, patent sutures and fontanelles, supernumerary teeth, short stature, and a variety of other skeletal changes. The disease gene is CBFA1/RUNX2, which is mapped to chromosome 6p21. Inactivation of the CBFA1/RUNX2 gene by mutations is involved in the skeletal defects that occur in patients with CCD. CBFA1/RUNX2 controls the differentiation of precursor cells into osteoblasts and is essential for membranous as well as endochondral bone formation. In this study of a 14-yr-old boy with typical CCD phenotype, the authors found a novel CBFA1/RUNX2 gene mutation. All of the amplified segment…

MaleHeterozygoteAdolescentDNA Mutational AnalysisCore Binding Factor Alpha 1 SubunitPolymerase Chain ReactionPedigreeAdolescent Chromosomes Human Pair 6 Cleidocranial Dysplasia/genetics* Cleidocranial Dysplasia/pathology Codon Nonsense/genetics* Core Binding Factor Alpha 1 Subunit/genetics* DNA Mutational Analysis DNA Primers/chemistry Female Gene Silencing Heterozygote Humans Male Pedigree Point Mutation* Polymerase Chain Reactioncleidocranial dysplasiaCodon NonsenseCBFA1/RUNX2HumansPoint MutationChromosomes Human Pair 6Femalegene mutationGene SilencingCleidocranial DysplasiaDNA Primers
researchProduct

Yersinia pestis DNA from Skeletal Remains from the 6th Century AD Reveals Insights into Justinianic Plague

2013

Yersinia pestis, the etiologic agent of the disease plague, has been implicated in three historical pandemics. These include the third pandemic of the 19th and 20th centuries, during which plague was spread around the world, and the second pandemic of the 14th–17th centuries, which included the infamous epidemic known as the Black Death. Previous studies have confirmed that Y. pestis caused these two more recent pandemics. However, a highly spirited debate still continues as to whether Y. pestis caused the so-called Justinianic Plague of the 6th–8th centuries AD. By analyzing ancient DNA in two independent ancient DNA laboratories, we confirmed unambiguously the presence of Y. pestis DNA in…

MaleHistoryYersinia pestis590Social and Behavioral SciencesPandemicBiology (General)16th CenturyPhylogenyHistory 15th CenturybiologyBacterialHistory 19th Century20th CenturyBiological AnthropologyHistory 16th Century17th CenturyFemaleBase Sequence; Bone and Bones; DNA Bacterial; Female; Genotype; History 15th Century; History 16th Century; History 17th Century; History 19th Century; History 20th Century; History Medieval; Humans; Male; Molecular Sequence Data; Pandemics; Yersinia pestis; Phylogeny; PlagueMedievalResearch ArticleDNA BacterialGenotypeQH301-705.5ImmunologyMolecular Sequence DataPlague (disease)MicrobiologyBone and BonesNOHistory 17th CenturyVirologyGeneticsHumansBase sequenceMolecular BiologyPandemicsBiologyPlague bacillus19th CenturyPlagueBase SequenceDNARC581-607History 20th Centurybiology.organism_classificationVirologyHistory Medieval15th CenturyAncient DNAYersinia pestisAnthropologyYersinia pestis DNAParasitologyImmunologic diseases. Allergy
researchProduct

Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe

2016

Transmitted human immunodeficiency virus drug resistance in Europe is stable at around 8%. The impact of baseline mutation patterns on susceptibility to antiretroviral drugs should be addressed using clinical guidelines. The impact on baseline susceptibility is largest for nonnucleoside reverse transcriptase inhibitors.

MaleHuman immunodeficiency virus 1EtravirineRNA directed DNA polymerase inhibitordarunavirHIV InfectionsSettore MED/42 - Igiene Generale E Applicata:Disciplines and Occupations::Health Occupations::Medicine::Public Health [Medical Subject Headings]:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]Salud públicageneticsInhibidores de proteasas:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Vital Statistics::Morbidity::Prevalence [Medical Subject Headings]atazanavirmedia_commontransmission:Geographicals::Geographic Locations::Europe [Medical Subject Headings]3. Good healthmicrobial sensitivity testpriority journalEurope ; HIV-1 ; antiretroviral therapy ; drug resistance ; transmissionHIV/AIDSlamivudineReverse Transcriptase Inhibitors/pharmacologyanti human immunodeficiency virus agentDrugMicrobiology (medical)medicine.medical_specialtyantiviral susceptibility:Phenomena and Processes::Genetic Phenomena::Genetic Variation::Mutation [Medical Subject Headings]media_common.quotation_subjectantiretroviral therapy030106 microbiologyHIV Infections/drug therapy:Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiviral Agents::Anti-Retroviral Agents::Reverse Transcriptase Inhibitors [Medical Subject Headings]Microbial Sensitivity TestsRILPIVIRINEArticleEFAVIRENZ03 medical and health sciencestransmitted drug resistanceSDG 3 - Good Health and Well-beingHumansTransmissionhuman:Phenomena and Processes::Physiological Phenomena::Pharmacological Phenomena::Drug Resistance [Medical Subject Headings]REVERSE-TRANSCRIPTASE INHIBITORSRilpivirinaINTEGRASEMUTATIONSabacavirmajor clinical studyVirologyInfecciones por VIHRegimenAntiretroviral therapy; Drug resistance; Europe; HIV-1; Transmission; Medicine (all); Microbiology (medical); Infectious DiseaseschemistryDrug resistance:Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds 1-Ring::Oxazines::Benzoxazines [Medical Subject Headings]MutationHIV-10301 basic medicinenevirapineDrug resistanceCommunicable diseases:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Confidence Intervals [Medical Subject Headings]chemistry.chemical_compoundantiviral therapyINFECTIONMedicine and Health SciencesPrevalence:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Surveys and Questionnaires [Medical Subject Headings]ViralNon-U.S. Gov'tReverse-transcriptase inhibitorantiretrovirus agentResearch Support Non-U.S. Gov'tMedicine (all)Human immunodeficiency virus infected patientMiddle AgedvirologyPREVALENCEAntiretroviral therapyEncuestas y CuestionariosANTIRETROVIRAL TREATMENTEuropeInfectious DiseasesHIV-1/drug effectsHIV Protease Inhibitors/pharmacologyRilpivirineReverse Transcriptase Inhibitors:Diseases::Immune System Diseases::Immunologic Deficiency Syndromes::HIV Infections [Medical Subject Headings]FemaleHIV drug resistancemedicine.drugAdultHuman immunodeficiency virus proteinase inhibitor:Chemicals and Drugs::Organic Chemicals::Nitriles::Rilpivirine [Medical Subject Headings]EfavirenzAnti-HIV AgentsResearch SupportResistencia a medicamentosSettore MED/17 - MALATTIE INFETTIVEantiviral resistanceInternal medicineAnti-HIV Agents/pharmacologyDrug Resistance ViralJournal Articlemedicine:Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Protease Inhibitors [Medical Subject Headings]abacavir plus lamivudineEuropa (Continente)Antiretroviral therapy; Drug resistance; Europe; HIV-1; Transmission; Adult; Anti-HIV Agents; Drug Resistance Viral; Europe; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Mutation; Prevalence; Reverse Transcriptase Inhibitors; Microbiology (medical); Infectious DiseasesemtricitabinenonhumanIntervalos de confianzadrug resistanceMutaciónAntiretroviral therapy; Drug resistance; Europe; HIV-1; Transmissionbusiness.industryHIVpredictionInhibidores de la transcriptasa inversaHIV Protease InhibitorsHuman immunodeficiency virus 1 infectiontenofovirINDIVIDUALSDrug Resistance Viral/geneticsBenzoxazinasETRAVIRINEdrug effects3121 General medicine internal medicine and other clinical medicinePrevalenciabusiness
researchProduct

Novel SCNN1A gene splicing-site mutation causing autosomal recessive pseudohypoaldosteronism type 1 (PHA1) in two Italian patients belonging to the s…

2021

Abstract Introduction Pseudohypoaldosteronism type 1 (PHA1) is a rare genetic disease due to the peripheral resistance to aldosterone. Its clinical spectrum includes neonatal salt loss syndrome with hyponatremia and hypochloraemia, hyperkalemia, metabolic acidosis and increased plasmatic levels of aldosterone. Two genetically distinct forms of disease, renal and systemic, have been described, showing a wide clinical expressivity. Mutations in the genes encoding for the subunits of the epithelial sodium channels (ENaC) are responsible for generalized PHA1. Patients’ presentation We hereby report on two Italian patients with generalized PHA1, coming from the same small town in the center of S…

MaleHyperkalemiaPseudohypoaldosteronismENaCCase ReportGene mutationBioinformaticsPediatricsRJ1-570chemistry.chemical_compoundConsanguinityYoung AdultNext generation sequencingmedicineHumansFamily historyEpithelial Sodium ChannelsSicilyENaC Next generation sequencing SCNN1A gene Splicing mutation Consanguinity Epithelial Sodium Channels Female Humans Infant Newborn Male Mutation Pseudohypoaldosteronism Sicily Young AdultAldosteronebusiness.industryInfant NewbornPseudohypoaldosteronismmedicine.diseasechemistrySCNN1A geneMutation (genetic algorithm)MutationFemalemedicine.symptombusinessHyponatremiaSplicing mutationAuntItalian Journal of Pediatrics
researchProduct

Novel mutations of CETP gene in Italian subjects with hyeralphalipoproteinemia

2009

Abstract Cholesteryl ester transfer protein (CETP) is a plasma glycoprotein that catalyses the transfer of cholesteryl esters from HDL to the other plasma lipoproteins. Genetic deficiency of CETP is one of the known causes of elevation of plasma HDL-C (primary hyperalphalipoproteinemia, HALP). We sequenced CETP gene in a group of 24 Italian subjects with primary HALP (HDL-C>80 mg/dl) suspected to have CETP deficiency. Two unrelated subjects both coming from the same geographical district, were found to be heterozygous for a nucleotide substitution in exon 6 (c.544C>T) and another subject was found to be heterozygous for a C>T transition in exon 9 (c.802C>T). Both mutations introduce a prema…

MaleHyperlipoproteinemiasMessengerDNA Mutational Analysismedicine.disease_causeExonFamilial hyperalphalipoproteinemiaChlorocebus aethiopsCETP activity; CETP gene mutations; Familial hyperalphalipoproteinemia; HDL size; Adolescent; Adult; Aged; Animals; Biomarkers; COS Cells; Cercopithecus aethiops; Cholesterol Ester Transfer Proteins; Cholesterol HDL; DNA Mutational Analysis; European Continental Ancestry Group; Female; Humans; Hyperlipoproteinemias; Italy; Male; Middle Aged; Phenotype; RNA Messenger; Transfection; Up-Regulation; Young Adult; Mutation; Cardiology and Cardiovascular MedicineGeneticsMutationTransition (genetics)biologyCETP activityMiddle AgedUp-RegulationCholesterolPhenotypeItalyCOS CellsRNA splicingFemaleFamilial hyperalphalipoproteinemia; CETP gene mutations; CETP activity; HDL sizelipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicineAdultHDLAdolescentEuropean Continental Ancestry GroupSocio-culturaleHDL sizeTransfectionWhite PeopleCercopithecus aethiopsYoung AdultCETP gene mutationsCholesterylester transfer proteinmedicineAnimalsHumansRNA MessengerGeneAgedCholesterol HDLIntroncetpCholesterol Ester Transfer Proteinscarbohydrates (lipids)biology.proteinRNAmutationBiomarkersMinigene
researchProduct

Urethrocutaneous fistula repair after hypospadias surgery

2003

To evaluate and compare the success rates of simple and layered repairs of urethrocutaneous fistulae after hypospadias repair.The charts of 72 children who developed fistulae after hypospadias repair were reviewed; 39 had a simple closure of the fistula, whereas 32 had a 'pants over vest' repair, in all cases after excluding an impairment of urine outflow.The success rate at the first attempt was 74% for simple closure and 94% for the layered repair; at the second attempt it was 80% and 100%, the difference being statistically significant for both repairs.Although probably far from an optimal technique for repairing urethrocutaneous fistulae, the pants-over-vest repair allows a good success…

MaleHypospadiasChild; Cutaneous Fistula; Humans; Hypospadias; Male; Postoperative Complications; Retrospective Studies; Surgical Flaps; Treatment Outcome; Urethral Diseases; Urinary FistulaUrinary FistulaCutaneous FistulaUrethral DiseaseSurgical FlapsSurgical FlapPostoperative ComplicationsTreatment OutcomeRetrospective StudieUrethral DiseasesHumansHypospadiaPostoperative ComplicationChildHumanRetrospective Studies
researchProduct

Identification of Naïve Hcv-1 Patients with Chronic Hepatitis who may Benefit from Dual Therapy with Peg-Interferon and Ribavirin.

2014

Background & Aims The pool of HCV genotype 1 patients likely to be cured by peg-interferon and ribavirin remains to be quantified. Methods In 1045 patients treated with peg-interferon and ribavirin, two therapeutic strategies were confronted: the first one evaluated only baseline variables associated with sustained virological response (SVR), and the second one included the rapid virologic response (RVR) in addition to baseline predictors. An 80% SVR rate was the threshold to retain a strategy as clinically relevant. Results Overall, 414 patients (39.6%) attained SVR. In the first strategy, the hierarchy of features independently associated with SVR was IL28B CC genotype (OR 5.082; CI 3.637…

MaleIL28BChronic HCV liver diseaseHepacivirusGastroenterologyPolyethylene GlycolsVirological responseresponse predictorschemistry.chemical_compoundantiviral therapyGenotypeViralChronicchronic hepatitis C; antiviral therapy; response predictorsSettore MED/12 - Gastroenterologiavirus diseasesMiddle AgedHepatitis CRecombinant ProteinsCombinationHCVFemalePredictors of response; Ribavirin; Peg-interferon; HCV; Chronic HCV liver diseaseAdultmedicine.medical_specialtyGenotypeChronic HCV liver disease; HCV; Peg-interferon; Predictors of response; Ribavirin; Adult; Aged; Antiviral Agents; Drug Therapy Combination; Female; Genotype; Hepacivirus; Hepatitis C Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; RNA Viral; Recombinant Proteins; Ribavirin; HepatologyPredictors of responseViremiaAntiviral AgentsDrug TherapyChronic hepatitisInternal medicineRibavirinmedicinechronic hepatitis CHumansDual therapyRapid Virologic ResponseAgedgenotype 1Peg-interferonHepatologybusiness.industryRibavirinInterferon-alphamedicine.diseasedigestive system diseasesSurgeryPeg interferonPegIFNchemistryRNAbusiness
researchProduct

Cumulative Prognostic Score Predicting Mortality in Patients Older Than 80 Years Admitted to the ICU

2019

OBJECTIVES To develop a scoring system model that predicts mortality within 30 days of admission of patients older than 80 years admitted to intensive care units (ICUs). DESIGN Prospective cohort study. SETTING A total of 306 ICUs from 24 European countries. PARTICIPANTS Older adults admitted to European ICUs (N = 3730; median age = 84 years [interquartile range = 81‐87 y]; 51.8% male). MEASUREMENTS Overall, 24 variables available during ICU admission were included as potential predictive variables. Multivariable logistic regression was used to identify independent predictors of 30‐day mortality. Model sensitivity, specificity, and accuracy were evaluated with receiver operating characteris…

MaleINTENSIVE-CARE-UNITOrgan Dysfunction Scoresmedicine.medical_treatmentPrognosis.MedizinDECISION-MAKINGLogistic regressionlaw.inventionolder adult0302 clinical medicinePHYSICIANSInterquartile rangelaw80 and overMedicine and Health Sciences030212 general & internal medicineHospital MortalityProspective StudiesProspective cohort studyolder adultsAged 80 and overpredictddc:617Respiration[SDV.MHEP.GEG]Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontologyBrief ReportPrognosisIntensive care unitADMISSION3. Good healthEuropeHospitalizationIntensive Care UnitsBrier scoreOlder adultsArtificialFemaleprognosimedicine.medical_specialtycritical care; model; older adults; predict; prognosis; Aged 80 and over; Europe; Female; Hospital Mortality; Hospitalization; Humans; Intensive Care Units; Male; Prospective Studies; Respiration Artificial; Organ Dysfunction Scores; Prognosis03 medical and health sciencesIntensive caremedicineJournal ArticleHumansILL ELDERLY-PATIENTSRenal replacement therapyAgedmodelReceiver operating characteristicbusiness.industry030208 emergency & critical care medicineRespiration Artificialcritical careEmergency medicine[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieBrief ReportsprognosisGeriatrics and Gerontologybusiness
researchProduct

2017 WSES guidelines for the management of iatrogenic colonoscopy perforation

2017

Abstract Iatrogenic colonoscopy perforation (ICP) is a severe complication that can occur during both diagnostic and therapeutic procedures. Although 45–60% of ICPs are diagnosed by the endoscopist while performing the colonoscopy, many ICPs are not immediately recognized but are instead suspected on the basis of clinical signs and symptoms that occur after the endoscopic procedure. There are three main therapeutic options for ICPs: endoscopic repair, conservative therapy, and surgery. The therapeutic approach must vary based on the setting of the diagnosis (intra- or post-colonoscopy), the type of ICP, the characteristics and general status of the patient, the operator’s level of experienc…

MaleIatrogenic DiseaseColonoscopyReviewIatrogenic colonoscopy perforation0302 clinical medicine80 and overOpen abdomenAged 80 and overintegumentary systemmedicine.diagnostic_testmusculoskeletal neural and ocular physiologylcsh:Medical emergencies. Critical care. Intensive care. First aidDisease ManagementIatrogenic colonoscopy perforation Colonoscopy Gastrointestinal endoscopy Emergency surgery Laparoscopy Antibiotic therapy Intra-abdominal infection Open abdomenColonoscopyMiddle Agedhumanities030220 oncology & carcinogenesisEmergency surgeryEmergency MedicineFemale030211 gastroenterology & hepatologymedicine.medical_specialtyColonPerforation (oil well)lcsh:SurgeryGuidelines as TopicSigns and symptomsGeneral status03 medical and health sciencesTherapeutic approachIntra-abdominal infectionEmergency surgerymedicineHumansGastrointestinal endoscopyIntensive care medicineAgedbusiness.industrylcsh:RD1-811lcsh:RC86-88.9Antibiotic therapyEndoscopic Procedurenervous system diseasesSettore MED/18 - Chirurgia GeneraleIntestinal PerforationAntibiotic therapy; Colonoscopy; Emergency surgery; Gastrointestinal endoscopy; Iatrogenic colonoscopy perforation; Intra-abdominal infection; Laparoscopy; Open abdomen; Aged; Aged 80 and over; Colon; Colonoscopy; Disease Management; Female; Humans; Intestinal Perforation; Male; Middle Aged; Guidelines as Topic; Iatrogenic DiseaseAntibiotic therapy; Colonoscopy; Emergency surgery; Gastrointestinal endoscopy; Iatrogenic colonoscopy perforation; Intra-abdominal infection; Laparoscopy; Open abdomen;LaparoscopySurgerySurgical devicebusiness
researchProduct